VivoSeq
Infectious Disease

Leishmaniasis

18

Pipeline Programs↗

4

Active Trials↗

9

Companies Involved↗

Leishmaniasis is an emerging landscape with 18 programs across 9 companies. The most active players are Pfizer, Knight Therapeutics (USA) Inc, Validus Pharmaceuticals. 7 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

71/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 2K

Knight Therapeutics (USA) Inc

1 program

Phase 3V

Validus Pharmaceuticals

1 program

Phase 3Gilead logo

Gilead

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedF

Fresenius Kabi Oncology Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

20 of 22 classified programs — the dominant modality here.

9%ALL OTHERSVaccine29%

Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

20

clinical trials

Completed10 · 50%
Recruiting4 · 20%
Withdrawn3 · 15%
Terminated1 · 5%
No longer available1 · 5%
Unknown status1 · 5%

Clinical Trials

Trial Activity

20 trials

Treatment of Mucosal Bolivian Leishmaniasis
Recruiting·FFundacion Nacional de Dermatologia·Phase 3·NCT04799236·120 enrolled
Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis with Inhaled Pentamidine Plus Oral Miltefosine
Recruiting·FFundacion Nacional de Dermatologia·Phase 2·NCT06550609·30 enrolled
Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly
Recruiting·UUniversity of Brasilia·Phase 2/3·NCT06040489·100 enrolled
Host Response to Infection and Treatment in Leishmania Infection of Humans
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00344188·289 enrolled
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
Completed·AAccess to Advanced Health Institute (AAHI)·Phase 1·NCT00111514·48 enrolled
Liposomal Amphotericin in Disseminated Leishmaniasis
Completed·HHospital Universitário Professor Edgard Santos·Phase 3·NCT02025491·20 enrolled
Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)
Completed·AAB Foundation·Phase 2·NCT01635777·37 enrolled
Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
Completed·—·Phase 2·NCT01377974·40 enrolled
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
Completed·DDrugs for Neglected Diseases·Phase 3·NCT00255567·1,142 enrolled
Sodium Stibogluconate Treatment of Leishmaniasis
Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT00662012·414 enrolled
Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application
Completed·UU.S. Army Medical Research and Development Command·N/A·NCT00490230·108 enrolled
Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
Completed·UU.S. Army Medical Research and Development Command·Phase 1/2·NCT00657618·77 enrolled
Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis
Completed·AAB Foundation·Phase 1/2·NCT00373568·25 enrolled
Miltefosine for Mucosal Leishmaniasis
Completed·AAB Foundation·Phase 1/2·NCT00373776·75 enrolled
Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396
Terminated·UU.S. Army Medical Research and Development Command·Phase 2·NCT00657917·1 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)